Investigational New Drugs

, Volume 19, Issue 3, pp 249–254 | Cite as

Phase II Studies of Bryostatin-1 in Patients with Advanced Sarcoma and Advanced Head and Neck Cancer

  • B. Brockstein
  • B. Samuels
  • R. Humerickhouse
  • R. Arietta
  • P. Fishkin
  • J. Wade
  • J. Sosman
  • E.E. Vokes


Background. Bryostatin 1 is a marinederived macrolactone with antineoplasticactivity modulated through protein kinaseC, and with good activity in in vitro and in vivomodels. There are fewdrugs that offer palliation for metastaticsoft-tissue sarcoma and head and neckcancer, and drugs with new mechanisms ofaction warrant detailed disease specificstudy. Patients and methods. Twophase II studies for patients withincurable soft tissue sarcoma (12), or headand neck cancer (12) were conducted. Patients were treated with bryostatin,120 mg/m2/72 hours every 2 weeks for 3cycles prior to re-evaluation. Mostpatients had received priorchemotherapy. Results. No patientshad objective responses to therapy. Sixpatients had brief periods of diseasestabilization. Toxicity was generallymild, with myalgia being prominent (n=8). Hyponatremia, not previously described,occurred in 5 patients. The mechanism ofthis toxicity was unclear. Conclusions. Bryosytatin 1given as a single agent for advanced adult soft tissuesarcoma and head and neck cancer isinactive. Myalgia and hyponatremia werethe predominant toxicities.

bryostatin 1 head and neck cancer sarcoma toxicities hyponatremia myalgia 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Demitri GD, Elias AD: Results of single-agent and combination chemotherapy for advanced soft-tissue sarcomas. Hem Onc Clin N Am 9: 765–786, 1995Google Scholar
  2. 2.
    Brennan MF, Casper ES, Harrison LB: Soft Tissue sarcoma. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology, 5th ed. Lippincott Raven, Philadelphia, 1997, pp 1738–1788Google Scholar
  3. 3.
    Brockstein BE, Peabody TD, Simon MA. Soft Tissue Sarcomas. In: Vokes EE, Golomb HM (eds) Oncologic Therapies. Springer-Verlag, Berlin 1998, pp 925–953Google Scholar
  4. 4.
    Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and Neck Cancer. N Engl J Med 328: 184–194, 1993Google Scholar
  5. 5.
    Vokes EE, Athanasiadis I: Chemotherapy for squamous cell carcinoma of head and neck: The future is now. Ann Oncol 7: 15–29, 1996Google Scholar
  6. 6.
    Pettit GR, Herald CL, Doubek DL, et al: Isolation and structure of bryosytatin 1. J Am Chem Soc 1: 6846–6848, 1982Google Scholar
  7. 7.
    Zhang X, Zhang R, Zhao H, Cai H, Gush KA, Kerr RG, Pettit GR, Kraft AS: Preclinical pharmacology of natural product anticancer agent bryostatin 1, an activator of protein kinase C. Cancer Res 56: 802–808, 1996Google Scholar
  8. 8.
    Hocevar BA, Fields AP: Selective translocation of Beta-II protein kinase C to the nucleus of human promyelocytic (HL60) leukemia cells. J Biol Chem 266: 28–33, 1991Google Scholar
  9. 9.
    Division of Cancer Treatment. U.S. National Cancer Institute. Clinical Brochure, Bryostatin 1, NSC 339555. July, 1996Google Scholar
  10. 10.
    Weitman S, Langevin AM, Berkow RL, Thomas PJ, Hurwitz CA, Kraft AS, Dubowy RL, Smith DL, Bernstein M: A phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study. Clin Cancer Res 5: 2344–2348, 1999Google Scholar
  11. 11.
    Grant S, Roberts J, Poplin E, Tombes MB, Kyle B, Welch D, Carr M, Bear HD: Phase Ib trial of bryostatin 1 in patients with refractory malignancies. Clin Cancer Res 4: 611–618, 1998Google Scholar
  12. 12.
    Philip PA, Rea D, Thavasu, Carmichael J, Stuart NS, Rockett H, Talbot DC, Ganesan T, Pettit GR, Balkwill F et al: Phase I study of bryostatin I: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J Natl Cancer Inst 85: 1812–1818, 1993Google Scholar
  13. 13.
    Jayson GC, Crowther D, Prendeville J, McGown AT, Scheid C, Stern P, Young R, Brenchley P, Chang J, Owens S, Pettit GR: A phase I trial of bryostatin I in patients with advanced malignancy using a 24 hour intravenous infusion. Br J Cancer 72: 461–468, 1995Google Scholar
  14. 14.
    Varteresian ML, Mohammad RM, Eilender DS, Hulburd K, Rodriruez DH, Pemberton PA, Pluda J, Dan MD, Pettit G, Chen BDM, Al-Katib AM: Phase I study of bryostatin I in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Clin Oncol 16: 56–62, 1998Google Scholar
  15. 15.
    Propper DJ, Macaulay V, O'Byrne KJ, Braybrooke JP, Wilner SM, Ganesan TS, Talbot DC, Harris AL: A phase II study of bryostatin I in metastatic malignant melanoma. Br J Cancer 78: 1337–1341, 1998Google Scholar
  16. 16.
    Prendeville J, Crowther D, Thatcher et al: A phase I study of intravenous bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br J Cancer 72: 418–468, 1993Google Scholar
  17. 17.
    Wang S, Wang Z, Boise LH, Dent P, Grant S: Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL. Leukemia 13: 1564–1573, 1999Google Scholar
  18. 18.
    Basu A, Lazo JS: Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum (II) by bryostatin 1. Cancer Res 52: 3119–3124, 1992Google Scholar
  19. 19.
    Mohammad RM, al Katib A, Pettit GR, Sensenbrenner LL: Successful treatment of human Waldenstrom's macroglobulinemia with combination biological therapy and chemotherapy agents. Cancer Res 54: 165–168, 1994Google Scholar
  20. 20.
    Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro. Br J Cancer 77: 216–220, 1998Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • B. Brockstein
    • 1
  • B. Samuels
    • 2
  • R. Humerickhouse
    • 1
  • R. Arietta
    • 1
  • P. Fishkin
    • 3
  • J. Wade
    • 4
  • J. Sosman
    • 5
  • E.E. Vokes
    • 1
  1. 1.Section of Hematology/OncologyUniversity of Chicago HospitalsChicagoUSA
  2. 2.Section of Hematology/OncologyLutheran General HospitalPark RidgeUSA
  3. 3.Oncology/ Hematology Associates of Central ILUSA
  4. 4.Cancer Care SpecialistsDecaturUSA
  5. 5.Section of Hematology/OncologyUniversity of Illinois College of MedicineChicagoUSA

Personalised recommendations